Fatty acids are released from adipose tissue into the circulation after hydrolysis of intracellular triacylglycerols by hormone-sensitive lipase. Adipose tissue acquires fatty acids mainly through the action of lipoprotein lipase, which hydrolyses triacylglycerols (TG) carried in the circulation by chylomicrons and very-low-density lipoproteins. Complex autocrine, paracrine and endocrine factors contribute to the modulation of adipose tissue uptake and release of lipid substrates. The ®ne tuning of the balance between fat accretion and reduction remains incompletely understood. Exciting new avenues of research continue to unravel the nature of the complex processes that modulate the balance between adipocyte lipid uptake and release as well as the hormonal modulation of adipose metabolism, as witnessed by the presentations of this session. Signi®cantly, several observations presented herein suggest that the capacity of adipose tissue for uptake and release of lipids and its modulation by hormonal factors may alter energy balance, rather than merely adapt to the central regulation of energy metabolism.
The ®rst topic of the session, presented by Max Lafontan, concerned the modulation of adipose tissue lipolysis by catecholamines and atrial natriuretic peptides. Adipocyte lipolysis relies upon the rate limiting enzyme hormone sensitive lipase (HSL), which is modulated mainly by insulin and catecholamines. Although insulin is a powerful antilipolytic agent, the ®ndings summarised by Lafontan clearly underline a major involvement of the balance between the lipolytic and antilipolytic properties of catecholamines in the modulation of lipolysis in human adipose tissue. The relative importance of the lipolytic b (b 1 , b 2 and b 3 ) and antilipolytic a 2 adrenergic receptors (AR), and therefore the net action of catecholamines on lipolysis in human adipose tissue, differs according to gender, anatomical location, adipose depot size and age. For instance, visceral fat cells exhibit a higher b and lower a 2 responsiveness compared to subcutaneous fat cells, which may explain the greater ease with which visceral fat is mobilized compared to subcutaneous depots. Variations in b and a 2 adrenergic sensitivity in adipocytes may be predictive of dietinduced weight loss, pointing out the fact that, under controlled conditions of energy intake, adipose lipolysis may somehow in¯uence whole-body energy expenditure. Recent studies have shown that low and very low calorie diets result in alterations in several components of the lipolytic response, including HSL expression and function and b-AR mediated events. Moderate weight loss improves adipose cell lipolytic ef®ciency through increased b-and decreased a 2 -AR sensitivities. Regarding the a 2 -AR, a number of in vitro investigations have outlined their antilipolytic action and the variation in their abundance according to fat depots. Recent microdialysis studies by Lafontan's group aimed to assess in vivo the physiological relevance of a2-AR mediated pathways to the modulation of lipolysis. They were able to demonstrate a speci®c role for epinephrine in the modulation of lipolysis in subcutaneous fat during exercise through the activation of antilipolytic a 2 -AR. It was also shown that such an activation contributes to the blunted lipolysis noted in obese men during exercise. These ®ndings suggest that a 2 -AR may contribute to the resistance of subcutaneous fat to respond to low-calorie diets and to exercise programmes in obese subjects, and point to possible applications of a 2 -AR antagonists as adjuvant therapeutic agents in the treatment of obesity. Dr Lafontan's presentation concluded with the role of atrial natriuretic peptides (ANP) on adipocyte lipolysis. ANP is expressed in adipose tissue, which also contains ANP receptors. ANPs-exert a lipolytic action that is as strong as that of b-adrenergic agonists. Its mode of action involves cGMP-dependent pathways. The physiological role of this new lipolytic pathway remains, however, to be established. Together with the ®ndings of Ge Ârard Ailhaud's group on the adipose renin ± angiotensinogen system (see session on Endocrine functions of adipose tissue), the presence of ANP in adipose tissue suggests the tantalizing but still speculative possibility of an association between adipose tissue and blood pressure regulation.
Lipid acquisition by adipose tissue relies largely upon the hydrolysis of lipoprotein-bound triglycerides by lipoprotein lipase (LPL). The enzyme is found in most tissues and is modulated in ways that are speci®c to each tissue. The possibility that differential expression of LPL in storage (adipose) and oxidizing (muscle, brown adipose) tissues may in¯uence fat accretion Ð provided that concomitant adjustments in energy metabolism occur Ð renders this enzyme of great interest to the ®eld of obesity and lipid metabolism. Rudolf Zechner summarized a series of enticing studies on adipose tissue development, lipid oxidation and the lipoprotein pro®le in transgenic mice over-or underexpressing LPL in various tissues. When Zechner's and other groups overexpressed LPL in skeletal muscle, they observed a marked decrease in plasma triglycerides and HDL levels, and some resistance to diet-induced obesity. The latter observation supports the concept, termed`substrate steal', that an increase in lipid uptake by muscle (presumably followed by oxidation) may reduce lipid deposition in adipose tissue and therefore obesity. Overexpression of LPL in the heart uncovered a particularly powerful role of cardiac LPL on VLDL catabolism and plasma TG levels, whereas overexpression in the liver did not greatly affect the overall lipid pro®le. The LPL transgene was also expressed on an LPL knock-out background to drive its expression only in certain organs without expression of the endogenous LPL gene. As in humans totally lacking LPL, mice lacking LPL in adipose tissue displayed normal body fat mass when fed a nonpuri®ed diet. The lack of import of exogenous FFA was therefore compensated by other pathways such as de novo lipogenesis. Of interest, leptin-de®cient mice lacking adipose LPL were quite resistant to obesity. This observation again suggests that the capacity of adipose tissue to acquire lipids may somehow affect energy balance. Mice expressing LPL in the heart, but not in adipose tissue or skeletal muscle, did not display hypertriglyceridemia, again pointing to a powerful action of cardiac LPL on circulating TG. The ®ndings further suggest that the site of expression of LPL may be more important than overall intravascular availability for an ef®cient lipoprotein metabolism. Skeletal muscle of these mice appeared normal, suggesting that the use of glucose Ð and perhaps FFA derived from plasma albubin-bound FFA Ð was suf®cient to sustain normal energy metabolism. The signi®cance of LPL expression in macrophages has also been oulined by overand underexpression studies. The absence of LPL markedly reduced the susceptibility of mice to develop diet-induced atherosclerosis, whereas overexpression appeared to induce the atherogenic process in the artery wall. Therefore, whereas high LPL activity in peripheral tissues contributes to the maintenance of a lipoprotein pro®le with low atherogenic potential, large amounts of the enzyme in macrophages appear to favor atherogenesis. This again points to the importance of the site of LPL expression in the consequences of its physiological functions. Future work will use more physiological modes of tissue-speci®c expression of LPL such as conditional knock-out mice to assess its impact on lipid metabolism. Also, there is as yet no transgenic mouse overexpressing LPL speci®cally in adipose tissue. It will be of interest to determine whether these mice develop obesity, with or without its metabolic complications.
Although monogenic obesity is extremely rare in humans, several genes are suspected of increasing the susceptibility to developing obesity. Peter Arner's presentation identi®ed adipose tissue as a relevant target in the search for such genes. The study of candidate genes for obesity has indeed found that many of them control important functions in adipose tissue. The b 2 -adrenergic receptor (AR) is the dominant lipolytic adrenoceptor subtype in human adipose tissue, and it is downregulated in subcutaneous adipose tissue of obese subjects. Several polymorphisms have been reported which alter b 2 -AR function. The Gln27Glu polymorphism associates with obesity and appears to dampen the lipolytic response of adipose tissue to catecholamines in inactive, but not in physically active men. The b3-AR is also considered as a potential obesity gene. A Trp64Arg mutation in the b3-AR gene has been associated with decreased resting metabolic rate and obesity in some but not all populations. The importance of hormone-sensitive lipase (HSL) in adipocyte lipolysis renders this enzyme a prime candidate as an obesity gene. Several polymorphisms in the HSL gene have in fact been linked to obesity in various populations; however, these association ®ndings await functional studies to determine the impact of the mutations on adipocyte lipolysis. The peroxisome proliferator activated receptor (PPAR) g-2 modulates adipocyte differentiation and the expression of several genes in adipose tissue. The Pro115Gln polymorphism of this gene increases PPARg-2 activity and is associated with morbid obesity, whereas the Pro12Ala polymorphism, which decreases receptor activity, is linked to lower body mass index, suggesting a legitimate role of the nuclear receptor, whether direct or indirect, in energy balance. The uncoupling proteins constitute other logical candidates in the search for obesity genes. Whereas uncoupling protein 1 (UCP-1) mediates thermogenesis, the functions of the newer members of the family, UCP-2 and UCP-3, remain unclear. The search for associations between UCP-2 and -3 with obesity remains open at this time. However, despite the small amount of brown fat in humans, the A(À3826)G polymorphism of the UCP-1 gene appears to in¯uence body weight gain, and to exert synergistic effects when present along with the Trp64Arg polymorphism of the b3-AR gene. TNFa, also produced in adipose tissue, modulates the expression of several genes in adipose tissue. The cytokine leads to insulin resistance, promotes lipolysis and adipocyte apoptosis. A linkage between TNFa and body fat content has been demonstrated, but studies on the effect of polymorphisms on TNFa function are still lacking. The same holds true for the widely expressed low-density lipoprotein receptor (LDL-R) gene, whose function in adipose tissue is to mediate the uptake of lipids from remnant lipoproteins. A polymorphic marker near the locus for LDL-R displays a strong linkage to human obesity, but here again functional studies remain to be carried out. It is Adipose tissue metabolism Y Deshaies and J-P Despre Âs worthy of note that many of the associations between obesity and polymorphisms of several candidate genes have been found in women but not in men. Finally, widely expessed genes (b2-AR, TNFa, LDL-R) are liable to in¯uence energy balance in a number of ways besides acting directly on adipose tissue; however, genes coding for HSL, the b3-AR, UCP-1 and PPARg-2 are most likely to in¯uence obesity by directly altering fat cell metabolism, which presumably would in turn affect either energy intake or expenditure.
The association of visceral obesity with metabolic complications such as insulin resistance has been established unequivocally. The presentation by Nir Barzilai focused on the critical role played by leptin in body fat distribution and its consequences on insulin action. Although leptin is considered as a marker for total body fatness, the hormone appears to be more closely linked to visceral (VF) than to subcutaneous (SC) fat. Barzilai's group has shown that leptin infusion to obese rats decreases total fat mass as much as pair feeding does, but results in a larger relative loss of VF, indicating a direct action of the hormone on visceral depots that are independent of food intake. Leptin may therefore represent an important determinant of fat distribution. The stronger response of VF to leptin compared to SC may be due to a more marked lipolytic activation secondary to the leptin-induced stimulation of b-oxidation, either directly or via the badrenergic pathway, or to a higher susceptibility to leptin-induced apoptosis. Interestingly, removal of VF (10% of total body fat) greatly decreases leptin gene expression in SC. This may in turn increase food intake and eventually restore fat mass. Finally, leptin infusion dampens the expression of its own gene. Together, these ®ndings point to a bi-directional relationship between leptin and VF. The second part of the presentation concerned the relationship between VF and insulin action. As assessed by a hepatic ± pancreatic clamp, removal of VF was shown to dramatically improve hepatic insulin sensitivity. To delineate the contribution of VF reduction on the bene®cial effects of leptin on in vivo insulin action, three treatments (leptin infusion, b-adrenergic agonist CL-316, 243 infusion, severe caloric restriction) resulting in similar VF loss were compared. All three treatments improved hepatic insulin sensitivity to a similar extent. Barzilai argued that this was unlikely to be mediated by a reduction in the portal delivery of glycerol and fatty acids since their plasma concentrations were unchanged, but this conclusion would be strengthened by direct measurements in portal blood. Signi®cantly, glucose uptake by peripheral tissues during the hyperinsulinemic clamp was improved only by leptin, through increased glycogen synthesis. This may be related to the lipopenic action of leptin, particularly in muscle, via increased lipid oxidation. These ®ndings point to speci®c actions of leptin that are independent of those on ingestive behavior. Delineation of the direct actions of leptin on peripheral tissues and those that occur via centrally mediated effector pathways constitute an active area of current research.
The nutrient storage function of adipose tissue depends, among many other factors, on insulinmediated glucose uptake. Morris Birnbaum concluded the session on adipose tissue metabolism with an overview of the signaling pathway that mediates the action of insulin on glucose transport in the adipocyte, with particular emphasis on the serineathreonine protein kinase AktaPKB. By regulating the generation of ATP and providing the backbone for fatty acid and triglyceride synthesis, glucose is essential for fat storage. Glucose uptake by fat cells is facilitated by transporter proteins. Insulin stimulates glucose transport mainly through eliciting the translocation of GLUT4 transporters from the interior to the surface of the cell. The broad brushstrokes of the insulin signaling cascade include insulin binding to its receptor, phosphorylation of docking proteins such as insulin receptor substrate proteins (IRS), and activation of PI3-kinase, the lipid products of which activate a number of other proteins involved in various metabolic actions of insulin. In the case of insulin-stimulated GLUT4 translocation, one of the leading candidate downstream mediators of PI3-kinase activation is the PI3-kinase-dependent serineathreonine protein kinase AktaPKB. It is believed that lipid products of PI3-kinase bind to the enzyme and activate phosphoinositide-dependent kinases which activate AktaPKB through phosphorylation. The involvement of AktaPKB in insulin-mediated modulation of glucose metabolism is supported by several lines of evidence from a number of experimental approaches. AktaPKB also provides a possible explanation for the selective responsiveness of certain tissues to insulin, but not to other growth factors. Indeed, in insulin target cells such as adipocytes, Birnbaum's group has shown by a variety of experimental approaches that AktaPKB is phosphorylated only by insulin, and not by other growth factors such as PDGF, contrary to other upstream and downstream signaling molecules which were activated comparably by both insulin and PDGF. Birnbaum further showed that the speci®city of the activation of AktaPKB by insulin was present in the adipocyte, but not in undifferentiated pre adipocyte ®broblasts. The last part of Birnbaum's presentation focused on the possible involvement of AktaPKB in the development of resistance of glucose metabolism to the action of insulin (insulin resistance). This condition is associated with elevated intracellular levels of ceramide, the production of which is promoted by molecules that are though to mediate insulin resistance, such as TNFa and free fatty acids. Antagonism of the activation of AktaPKB is though to be the mechanism whereby elevated ceramide levels lead to insulin resistance. The site of modulation lies between activation of PI3-kinase and subsequent stimulation of AktaPKB. This mechanism also appears to mediate beta-cell apoptosis observed in the pancreas of type II diabetics. Much remains to be resolved as to the ®ne details of the workings of AktaPkB; however, it is clear that the enzyme constitutes an important participant in numerous insulinmediated responses.
The presentations heard in this session on adipose tissue metabolism, together with other recent ®ndings, support the notion that the capacity of adipose tissue to acquire and release lipids is able to alter whole body energy balance. The remaining challenge is to unveil how this is achieved. Thorough energy balance studies are needed to determine which of the energy balance components are affected by speci®c alterations in adipose tissue metabolism. Changes in the lipid storage and release properties of adipose tissue could, for instance, affect energy balance through adipose tissue endocrine functions (eg leptin) or through substrate-dependent alterations in the function of tissues involved in thermogenesis. Energy expenditure may be affected by adipose tissue metabolism through direct peripheral actions on thermogenic tissues or via centrally mediated pathways. Delineation of the complex means by which adipose tissue metabolism may affect energy balance constitutes an exciting avenue of investigation for the near future.
